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Abstract
Aims/hypothesis Previous studies have suggested that the haemoglobin glycation index (HGI) can be used as a predictor of
diabetes-related complications in individuals with type 1 and type 2 diabetes. We investigated whether HGI was a predictor of
adverse outcomes of intensive glucose lowering and of diabetes-related complications in general, using data from the Action in
Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Methods We studied participants in the ADVANCE trial with data available for baseline HbA1c and fasting plasma glucose (FPG)
(n = 11,083). HGI is the difference between observed HbA1c and HbA1c predicted from a simple linear regression of HbA1c on
FPG. Using Cox regression, we investigated the association between HGI, both categorised and continuous, and adverse out-
comes, considering treatment allocation (intensive or standard glucose control) and compared prediction of HGI and HbA1c.
Results Intensive glucose control lowered mortality risk in individuals with high HGI only (HR 0.74 [95% CI 0.61, 0.91]; p =
0.003), while there was no difference in the effect of intensive treatment on mortality in those with high HbA1c. Irrespective of
treatment allocation, every SD increase in HGI was associated with a significant risk increase of 14–17% for macrovascular and
microvascular disease and mortality. However, when adjusted for identical covariates, HbA1c was a stronger predictor of these
outcomes than HGI.
Conclusions/interpretation HGI predicts risk for complications in ADVANCE participants, irrespective of treatment allocation,
but no better than HbA1c. Individuals with high HGI have a lower risk for mortality when on intensive treatment. Given the
discordant results and uncertain relevance beyond HbA1c, clinical use of HGI in type 2 diabetes cannot currently be
recommended.
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Introduction
HbA1c is an established means of monitoring average blood
glucose levels and a surrogate marker of the effect of glucose-
lowering interventions [1]. It is highly associated with the risk
for diabetes-related complications, in particular those of mi-
crovascular origin [2–5]. Although HbA1c is almost universal-
ly accepted to guide and monitor diabetes treatment, its use in
clinical practice has arguable limitations. There is a proposed
inter-individual variation in the propensity for glycation, in
both healthy individuals and those with diabetes [6–13],
limiting the use of HbA1c as a one-size-fits-all measurement.
Moreover, the value of HbA1c as a surrogate endpoint was
questioned by the results of the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial, where
HbA1c lowering may have had detrimental effects on the risk
of premature mortality [14]. Therefore, ‘the lower the better’
may not universally hold for HbA1c, and additional
(bio)markers might be useful to individualise treatment targets
and risk prediction [15].
The haemoglobin glycation index (HGI) quantifies the
variation in the relation between HbA1c and the plasma glu-
cose concentration [16]. For any individual within a study
population, HGI is defined as the difference between the ob-
served HbA1c and the fitted value from a simple linear model
that predicts HbA1c from the fasting plasma glucose (FPG)
concentration, i.e. the residual from the fitted linear regression
line. In previous studies, HGI was normally distributed, stable
over time and consistent over a wide range of blood glucose
concentrations [17–20]. In an analysis in individuals with type
1 diabetes in the DCCT, a high HGI was associated with the
risk for and progression of retino- and nephropathy [21]. In an
analysis of the ACCORD trial, only participants in the highest
HGI third were at higher risk for mortality and those with high









intensive glucose lowering, in contrast to participants with a
low or intermediate HGI [16]. The use of HGI is not without
controversy, as in the DCCT population it was shown that the
effect of HGI on microvascular complications disappeared
after adjustment for the effect of HbA1c [22]. However, the
use of HbA1c in type 1 diabetes is undisputed, whereas in
individuals with type 2 diabetes, HbA1c seems to have short-
comings, as demonstrated by the ACCORD trial.
The aim of this study was to assess whether HGI is a pre-
dictor of adverse outcomes of intensive glucose-lowering
therapy and a predictor of diabetes-related complications in
the cohort of individuals with type 2 diabetes recruited for the
Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation
(ADVANCE) trial (ClinicalTrials.gov registration no.
NCT00145925) [23]. Additionally, we aimed to compare the
predictive values of HGI and HbA1c to assess the possible
added value of HGI beyond HbA1c.
Methods
ADVANCE trial
In the ADVANCE trial, 11,140 individuals with type 2 diabe-
tes and a history of, or a risk factor for, vascular disease were
randomised in a factorial design between two BP-lowering
strategies and two glucose-lowering strategies [24]. Glucose-
lowering treatment was either standard (based on local guide-
lines) or intensive, starting with gliclazide (30–120 mg daily,
modified release) and adding other medication as necessary
(based on the study protocol and discretion of the treating
physician) to achieve a HbA1c level of ≤48 mmol/mol
(≤6.5%). Primary endpoints were a composite of major
macro- and microvascular events. Study participants were,
on average, 66 years old, with a mean diabetes duration of
8 years and a mean baseline HbA1c of 59 mmol/mol (7.5%).
After a follow-up of 5 years, mean HbA1c was 48 mmol/mol
(6.5%) in the intensively treated group vs 56 mmol/mol
(7.3%) in the standard group. Intensive glucose-lowering
treatment reduced the combination of macro- and microvas-
cular events, mainly due to a 20% reduction in nephropathy, at
the cost of an 86% increase in the risk of severe
hypoglycaemia.
Present study
HGIWe excluded 57 individuals with missing baseline HbA1c
(n = 54) or baseline FPG (n = 3). For the 11,083 remaining
individuals, we fitted a linear regression. The linear regression
equation describing the relation between baseline HbA1c and
FPG in our population was HbA1c (%) = 4.5 + 0.356 × FPG
(mmol/l) (r2 = 0.40, Fig. 1a). Results from simple linear
regression were comparable with a cubic spline model, so
we chose the simpler linear model. We derived predicted
HbA1c by inserting FPG values into this regression equation.
Baseline HGI was calculated by subtracting predicted HbA1c
from observed HbA1c (equalling the residual from the
regression line, Fig. 1b). In this way, individuals with high
HGI will have a higher measured HbA1c than anticipated from
the FPG value. In accordance with existing literature, we di-
vided the population in three equally sized HGI groups (low,
intermediate and high). This study was conducted according
to the principles of the declaration of Helsinki [25] and in
accordance with the Dutch Medical Research Involving
Human Subjects Act (WMO). All participants provided writ-
ten informed consent for the original study.
Outcomes We analysed four predefined outcome measures:
(1) major macrovascular events, defined as death from cardio-
vascular cause, non-fatal myocardial infarction or non-fatal
stroke; (2) major microvascular events, defined as new or
worsening nephropathy or retinopathy; (3) total mortality;
and (4) severe hypoglycaemia. Severe hypoglycaemia was
defined as transient dysfunction of the central nervous system
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Fig. 1 (a) Regression of FPG on HbA1c. The dotted line represents the
simple linear regression line of the equation: HbA1c (%) = 4.5 +
0.356 × FPG (mmol/l), r2 = 0.40. (b) Plot of the residuals (HGI) vs the
fitted (predicted HbA1c) values (p=1.00). To convert values for HbA1c in
% into mmol/mol, subtract 2.15 and multiply by 10.929
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Statistical analysis We compared baseline characteristics bet-
ween the low, intermediate and high HGI groups using
ANOVA or Kruskal–Wallis tests for continuous variables, de-
pending on the distribution, andχ2 tests for categorical variables.
We used Cox proportional hazard regression models to analyse
the association between baseline HGI and time to event for all
four outcomes, with adjustment for covariates. We studied
separately: (1) the treatment-modifying effect of HGI; and (2)
the effect of HGI independent of treatment allocation—the first
tomake a comparisonwith the results from theACCORD reana-
lysis, the latter as it seems more relevant for use in clinical
practice where individuals will undergo variable treatment regi-
mens. To assess whether HGI was better than time-matched
(baseline) HbA1c we added HbA1c as a covariate to our models
and used HbA1c instead of HGI as predicting variable to com-
pare the effect on outcomes.
Treatment-modifying effect of HGI We investigated the effect
of intensive glucose control on outcomes across HGI groups,
by adding the interaction term between HGI group and treat-
ment allocation (intensive or standard glucose-lowering thera-
py) to the model with HGI and treatment. We adjusted the
model for age, sex, ethnic origin (Asian or non-Asian), BMI,
duration of type 2 diabetes, history ofmacro- andmicrovascular
events, current drinking and smoking habits, use of glucose-
lowering medication, use of BP-lowering drugs, systolic and
diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDL-
and total cholesterol and triacylglycerol. We added baseline
HbA1c to the before-mentioned covariates in a separate analy-
sis. Finally, we assessed the associations between HbA1c (in-
stead of HGI) as the exposure variable and outcomes, adjusted
for the same covariates and studied the interaction between
treatment and HbA1c.
Effect of HGI independent of treatment allocation We
assessed the association between HGI and outcomes, irrespec-
tive of treatment, for the low, intermediate and high HGI group,
as well as for HGI as a continuous variable. The low HGI
group served as the reference group in the comparison. We
adjusted for the identical set of standard covariates (with and
without HbA1c). Again, we assessed the associations between
HbA1c (instead of HGI) as the exposure variable and outcomes,
adjusted for the same covariates.
As only 1.5% of data were missing, no imputation was
carried out. Significance levels were set at a p < 0.05.
Statistical analyses were performed using SAS Enterprise
Guide 7.1 (SAS STAT 9.4; SAS Institute, Cary, NC, USA).
Results
In this population, HGI showed a normal distribution, ranging
from −6.46 to 8.99, with amean of 0 (SD 1.20).When dividing
the study population into thirds, HGI cut-off points were
≤−0.53 for the low, −0.52 to 0.28 for the intermediate and
≥0.29 for the high HGI group. Mean baseline HGI was
−1.14 (SD 0.57) in the low, −0.14 (SD 0.23) in the intermediate
and 1.29 (SD 0.99) in the high HGI group (Table 1).
There were some significant differences in baseline charac-
teristics between the HGI groups (Table 1). Individuals in the
high HGI group had the longest duration of diabetes and a
higher proportion used glucose-lowering medication. More
of those in the high HGI group were smokers, but fewer con-
sumed alcohol. The prevalence of previous microvascular
events was highest in the high HGI group. Almost half of
the individuals in the high HGI group were of Asian origin,
in contrast to a third in the low and intermediate group. HbA1c
levels increased from low to high HGI group and FPG was
lowest in the intermediate HGI group.
Treatment-modifying effect of HGI
Table 2 shows the adjusted HRs based on HGI group and
treatment allocation (intensive or standard glucose-lowering
therapy). The effect of treatment allocation on macro- and
microvascular complications was similar across the three
HGI groups. However, the effect of intensive therapy on mor-
tality risk differed between HGI groups (p for interaction =
0.011). In the high HGI group the mortality risk was signifi-
cantly lower with intensive therapy (adjusted HR 0.74 [95%
CI 0.61, 0.91]; p = 0.003), whereas intensive treatment did not
diminish risk for mortality in the low and intermediate groups.
This effect remained after additional adjustment for baseline
HbA1c level (electronic supplementary material (ESM)
Table 1). With regard to severe hypoglycaemia, absolute rates
increased progressively as HGI rose, regardless of whether
individuals received intensive or standard treatment. The ef-
fect of intensive treatment on the risk for severe
hypoglycaemia was not different between HGI thirds, as indi-
cated by the non-significant p value for interaction (0.228). To
compare the predictive value of HGI with HbA1c, we assessed
the interaction between treatment and HbA1c groups using the
same multivariable model (ESM Table 2). Here, there was no
difference in effect of intensive treatment on mortality risk
across the three HbA1c groups (p for interaction = 0.530).
Individuals with intermediate and high HbA1c were at greater
risk for severe hypoglycaemia when intensively treated, con-
trary to individuals with low HGI.
Effect of HGI independent of treatment allocation
Table 3 shows HRs for outcomes byHGI group irrespective of
treatment allocation, with the low HGI group as reference
group. In the multivariable analysis, individuals in the high
HGI group had a significantly higher risk for major
macrovascular events, compared with the low HGI group
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(HR 1.26 [95%CI 1.09, 1.46]; p = 0.002). Further, the risk for
major microvascular events and mortality was also higher in
the high HGI group compared with the low HGI group (HR
1.46 [95% CI 1.26, 1.69], p < 0.0001 and HR 1.36 [95% CI
1.17, 1.59], p < 0.0001, respectively). The risk of severe
hypoglycaemia did not differ between HGI groups. The effect
of HGI on these complications disappeared after additional
adjustment for HbA1c (ESM Table 3). Again, we assessed
the association between HbA1c groups and adverse outcomes
using the same multivariable model (ESM Table 4). Likewise,
the high HbA1c group had a higher risk for macro- and micro-
vascular complications and mortality compared with the low
HbA1c group. HRs exceeded those seen for HGI. HbA1c was
not associated with the risk of severe hypoglycaemia.
When we considered HGI as a continuous variable, every 1
SD (=1.20 HGI) increase resulted in a 14% risk increase for
microvascular complications, a 17% risk increase for
macrovascular complications and a 16% risk increase for mor-
tality (p < 0.0001) (Fig. 2). Continuous HGI was not associat-
ed with severe hypoglycaemia (HR 1.10 [95% CI 0.97, 1.25];
p = 0.123). Continuous HbA1c (1 SD = 1.56% HbA1c) was a
stronger predictor for the risk of microvascular events (HR
1.19 [95% CI 1.13, 1.26]; p < 0.0001), macrovascular events
(HR 1.31 [95% CI 1.24, 1.38]; p < 0.0001) and mortality (HR
1.14 [95% CI 1.14, 1.28]; p < 0.0001) than HGI.
Discussion
With this analysis of the ADVANCE trial we showed that HGI
predicts diabetes-related complications, but no better than
HbA1c. Irrespective of treatment allocation, the high HGI
group (i.e. individuals with higher HbA1c levels than would
be expected for their given fasting glucose levels) was at
higher risk for macro- and microvascular complications and
mortality compared with the low HGI group. Every SD in-
crease in HGI gave a significant 14–17% risk increase for
these three outcomes. Hypothetically, this could be explained
by a higher propensity for glycation of membrane proteins and
lipids other than haemoglobin, with these glycation products
leading to microvascular complications and atherogenesis.
This effect disappeared after additional adjustment for
HbA1c, which is in line with results on the effect of HGI in
individuals with type 1 diabetes in the DCCT [22]. However,
this might be considered over-adjustment, as HGI is so strong-
ly related to HbA1c (HGI is HbA1c corrected for FPG).
Table 1 Baseline characteristics of individuals by HGI group
Characteristic Low HGI, n=3694 Intermediate HGI, n=3696 High HGI, n=3693 p valuea
HGI (%) −1.14 ± 0.57 −0.14 ± 0.23 1.29 ± 0.99
HbA1c (mmol/mol) 45.0 (40.0–52.0) 54.0 (49.0–60.0) 69.0 (61.0–81.0) <0.0001
HbA1c (%) 6.30 (5.80–6.90) 7.06 (6.60–7.60) 8.50 (7.71–9.60) <0.0001
FPG (mmol/l) 8.10 (6.83–10.00) 7.60 (6.40–9.10) 8.10 (6.60–10.20) <0.0001
Age (years) 65.89 ± 6.38 66.28 ± 6.43 65.18 ± 6.32 <0.0001
Female sex 1543 (41.8) 1524 (41.2) 1635 (44.3) 0.019
BMI (kg/m2) 28.36 ± 5.10 28.61 ± 5.26 28.05 ± 5.19 <0.0001
Diabetes duration (years) 6 (2–11) 6 (3–11) 8 (4–12) <0.0001
Asian ethnicity 1234 (33.4) 1233 (33.4) 1750 (47.4) <0.0001
Current smoker 499 (13.5) 578 (15.6) 598 (16.2) 0.003
Current drinker 1298 (35.1) 1245 (33.7) 835 (22.6) <0.0001
Systolic BP (mmHg) 145.56 ± 21.56 144.81 ± 21.13 144.67 ± 21.90 0.164
Diastolic BP (mmHg) 80.87 ± 10.87 80.49 ± 10.93 80.54 ± 10.97 0.260
eGFR (ml min−1 [1.73 m]−2) 74.54 (62.53–87.60) 74.73 (62.25–88.17) 75.25 (61.37–89.88) 0.527
HDL-cholesterol (mmol/l) 1.28 ± 0.37 1.25 ± 0.34 1.24 ± 0.34 <0.0001
LDL-cholesterol (mmol/l) 3.11 ± 1.04 3.06 ± 1.00 3.16 ± 1.05 0.0001
Total cholesterol (mmol/l) 5.20 ± 1.19 5.14 ± 1.12 5.25 ± 1.26 0.001
Triacylglycerol (mmol/l) 1.60 (1.16–2.30) 1.60 (1.19–2.30) 1.70 (1.20–2.40) 0.001
Glucose-lowering medication 3256 (88.1) 3326 (90.0) 3496 (94.7) <0.0001
Insulin 42 (1.1) 43 (1.2) 70 (1.9) 0.007
BP-lowering medication 2865 (77.6) 2773 (75.0) 2694 (72.9) <0.0001
Past microvascular event 315 (8.5) 357 (9.7) 481 (13.0) <0.0001
Past macrovascular event 1187 (32.1) 1179 (31.9) 1206 (32.7) 0.776
Values are presented as mean ± SD, median (IQR) or proportion (%)
a Two-sided p values for overall differences between HGI groups from ANOVA, Kruskal–Wallis or χ2 tests
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Therefore, we separately assessed the effect of HbA1c on out-
comes using the samemodel and found that HbA1c was just as
strong or even stronger for predicting complications in this
cohort of individuals with type 2 diabetes. To our knowledge,
this is the first time the predictive value of HGI has been
compared with that of HbA1c in this way. As HbA1c does
not need a population regression equation as does HGI, this
makes HbA1c more straightforward and convenient to use.
In our study, intensive treatment carried a lower risk for
mortality in individuals with a high HGI, whereas it had no
effect on mortality in individuals with a low or intermediate
HGI. Thus, a high HGI identified a group of people who
benefitted most from intensive HbA1c-lowering treatment in
terms of mortality. This finding remained after additional cor-
rection for baseline HbA1c, but was not replicated by using
HbA1c as the predicting variable, as we found no interaction
between treatment and HbA1c groups. Overall, the estimates
for the effect of intensive treatment as shown in Table 2
remained unchanged after additional adjustment for HbA1c
(ESM Table 1), which is not surprising given that HGI is just
a linear function of HbA1c and FPG (i.e. it is HbA1c – (a + b ×
FPG), where a and b are regression coefficients). The above
directly opposes the results of an analysis of the ACCORD
trial, where intensive treatment was associated with a signifi-
cantly higher, instead of lower, risk for mortality in partici-
pants with a high HGI [16]. Thus, the hypothesis put forward
that a high HGI results in more complications due to more
intensive treatment to lower HbA1c than is necessary to lower
plasma glucose is not supported by our study.
The inconsistency between the effect of HGI on outcomes
in these two large outcome studies might be explained by
important differences between ACCORD and ADVANCE.
First, glucose-treatment strategies were different, although
both took HbA1c as predominant measure of glycaemia and
both took glucose into account. Glycaemic treatment in
ACCORD was intensified when HbA1c level was
Table 2 Multivariable Cox proportional hazard regression analysis for major macrovascular events, major microvascular events, total mortality and
severe hypoglycaemia predicted by treatment and HGI group
Intensive treatment Standard treatment Adjusted HRe p value for
interactionf
Events by HGI group At risk (n) Events (n) %d At risk (n) Events (n) %d Estimate (95% CI) p value
Major macrovascular eventsa
Overall 5542 555 5.0 5541 587 5.3 0.95 (0.84, 1.07) 0.403 0.124
Low HGI 1873 180 4.9 1821 164 4.4 1.12 (0.91, 1.39) 0.297
Intermediate HGI 1829 167 4.5 1867 178 4.8 0.92 (0.74, 1.14) 0.436
High HGI 1840 208 5.6 1853 245 6.6 0.84 (0.69, 1.01) 0.059
Major microvascular eventsb
Overall 5542 526 4.7 5541 603 5.4 0.87 (0.77, 0.99) 0.029 0.845
Low HGI 1873 141 3.8 1821 159 4.3 0.84 (0.67, 1.06) 0.136
Intermediate HGI 1829 148 4.0 1867 178 4.8 0.87 (0.70, 1.08) 0.216
High HGI 1840 237 6.4 1853 266 7.2 0.91 (0.77, 1.09) 0.314
Total mortality
Overall 5542 494 4.5 5541 531 4.8 0.95 (0.84, 1.08) 0.420 0.011
Low HGI 1873 160 4.3 1821 137 3.7 1.17 (0.93, 1.47) 0.181
Intermediate HGI 1829 160 4.3 1867 162 4.4 0.98 (0.79, 1.23) 0.887
High HGI 1840 174 4.7 1853 232 6.3 0.74 (0.61, 0.91) 0.003
Severe hypoglycaemiac
Overall 5542 149 1.3 5541 81 0.7 1.82 (1.38, 2.40) <0.0001 0.228
Low HGI 1873 34 0.9 1821 24 0.6 1.34 (0.79, 2.27) 0.276
Intermediate HGI 1829 49 1.3 1867 28 0.8 1.82 (1.14, 2.90) 0.012
High HGI 1840 66 1.8 1853 29 0.8 2.45 (1.57, 3.85) <0.0001
aMajor macrovascular events were defined as death from a cardiovascular cause, non-fatal myocardial infarction or stroke
bMajor microvascular events were defined as new or worsening nephro- or retinopathy
c Severe hypoglycaemic episodes were defined as transient dysfunction of the central nervous system with the inability to treat oneself
d Percentage of events respective to the total cohort (overall, n=11,083; low HGI, n=3694; intermediate HGI, n=3696; high HGI, n=3693)
eModel was adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration of type 2 diabetes, history of macro- and microvascular events,
current drinking and smoking, use of glucose-lowering drugs, use of BP-lowering drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR),
LDL-, HDL- and total cholesterol, triacylglycerol
f p value for interaction between treatment effect and HGI group
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≥42 mmol/mol (≥6%) or when >50% of the self-monitored
pre- or 2 h post-meal capillary glucose values were above a
certain threshold [26].The treatment algorithm of the
ADVANCE trial took discrepancies between HbA1c levels
and blood glucose values into account simultaneously [23].
When HbA1c level was >47 mmol/mol (>6.5%) but fasting
glucose was relatively low, mealtime interventions were
optimised and the reliability of the tests was checked. Also
ACCORD had participants who started with a higher HbA1c
and had a lower target HbA1c in the intensive group. Further,
30% more individuals under intensive treatment received in-
sulin in ACCORD compared with ADVANCE [5]. This is in
agreement with the observation that FPG was treated more
aggressively in ACCORD, with a decrease of 3.3 mmol/l from
baseline to end of trial, compared with 1.9 mmol/l in
ADVANCE. Moreover, in ADVANCE all participants re-
ceived a sulfonylurea derivative at the start, while in
ACCORD thiazolidinedione treatment was frequently used.
The additional treatments differed between studies (i.e. use
of aspirin and statins was substantially higher in ACCORD).
Second, ACCORD was terminated prematurely, limiting the
follow-up, and potentially misrepresenting estimates (no ad-
justment to standard errors was made for early stopping).
Third, ADVANCE and ACCORD were discordant in the ma-
jor findings, including mortality. In ACCORD, mortality rates
were significantly higher in the intervention arm compared
with the control arm [14], whereas in ADVANCE there were
no significant differences in mortality between arms [23]. Post
hoc, it was shown that intensively treated ACCORD partici-
pants with a high average on-treatment HbA1c (>53 mmol/
mol [>7%]) were at greater risk for mortality than intensively
treated participants with average HbA1c <53mmol/mol (<7%)
or standard-treated individuals with average HbA1c
>53 mmol/mol (>7%) [27]. The number of individuals
experiencing severe hypoglycaemia was significantly higher
with intensive treatment in both studies, but the event rates per
person-year were higher in the ACCORD trial (3.5% per year
with intensive treatment vs 1.0% per year in the control arm),
whereas in ADVANCE rates were 0.7% per year in intensive
treatment vs 0.4% per year in the control arm. We found no
Table 3 Cox proportional hazard regression analysis for major macrovascular events, major microvascular events, total mortality and severe
hypoglycaemia predicted by HGI group (using the low group as a reference)
Unadjusted HR Adjusted HRd
Events by HGI group At risk (n) Events (n) % Estimate 95% CI p value (vs low) Estimate 95% CI p value (vs low)
Major macrovascular eventsa
Overall 11,083 1142 10.3
Low HGI 3694 344 9.3
Intermediate HGI 3696 345 9.3 1.00 (0.86, 1.16) 0.989 0.97 (0.84, 1.13) 0.738
High HGI 3693 453 12.3 1.35 (1.17, 1.55) <0.0001 1.26 (1.09, 1.46) 0.002
Major microvascular eventsb
Overall 11,083 1129 10.2
Low HGI 3694 300 8.1
Intermediate HGI 3696 326 8.8 1.09 (0.93, 1.27) 0.286 1.09 (0.93, 1.27) 0.306
High HGI 3693 503 13.6 1.77 (1.53, 2.04) <0.0001 1.46 (1.26, 1.69) <0.0001
Total mortality
Overall 11,083 1025 9.2
Low HGI 3694 297 8.0
Intermediate HGI 3696 322 8.7 1.09 (0.93, 1.27) 0.300 1.01 (0.86, 1.19) 0.865
High HGI 3693 406 11.0 1.39 (1.19, 1.61) <0.0001 1.36 (1.17, 1.59) <0.0001
Severe hypoglycaemiac
Overall 11,083 230 2.1
Low HGI 3694 58 1.6
Intermediate HGI 3696 77 2.1 1.30 (0.91, 1.84) 0.144 1.25 (0.88, 1.77) 0.219
High HGI 3693 95 2.6 1.56 (1.11, 2.20) 0.010 1.33 (0.94, 1.89) 0.110
aMajor macrovascular events were defined as death from a cardiovascular cause, non-fatal myocardial infarction or stroke
bMajor microvascular events were defined as new or worsening nephro- or retinopathy
c Severe hypoglycaemic episodes were defined as transient dysfunction of the central nervous system with the inability to treat oneself
dModel was adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration of type 2 diabetes, history of macro- and microvascular events,
current drinking and smoking, use of glucose-lowering drugs, use of BP-lowering drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR),
LDL-, HDL- and total cholesterol, triacylglycerol
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observable difference in the effect of HGI on severe
hypoglycaemia due to intensive treatment, although the abso-
lute rates and adjusted hazard ratios increased as HGI rose.
With regard to HbA1c, individuals with intermediate and high
HbA1c were at greater risk for severe hypoglycaemia when
intensively treated compared with individuals with low
HbA1c, a finding consistent with previous literature [28].
Baseline characteristics of individuals with high HGI
accorded with previous studies [16, 29]. The ethnic differences
(i.e. more Asians in the high HGI group) are consistent with the
observation that ethnicity influences the haemoglobin
glycation, with, in general, relative higher HbA1c levels in
non-whites [17, 30–33]. However, regression equations in
Asian (HbA1c = 4.6 + 0.373 × FPG, r
2 = 0.41) and non-Asian
(HbA1c = 4.5 + 0.340 × FPG, r
2 = 0.40) participants were very
similar. The combination of a slightly younger age, longer du-
ration of diabetes (on average 2 years), more use of glucose-
lowering medication and higher rates of microvascular compli-
cations suggests that individuals with high HGI might have a
form of diabetes that is more difficult to treat. This in itself can
be the cause of diabetes-related complications, but there is also
potential for confounding, as these characteristics could well be
explained by the higher HbA1c levels in individuals with high
HGI [22]. The HGI concept is based on the proposed inter-
individual variation in haemoglobin glycation, while an ade-
quate method for measuring glycation rate is lacking.
Erythrocyte lifespan is a major determinant of the variation in
haemoglobin glycation and subtle natural variation in
senescence of erythrocytes is complex to quantify [34, 35]. To
our knowledge, there are no studies focusing on the pathophys-
iological mechanism explaining both the biological variation in
haemoglobin glycation as well as the reason for the possible
increased risk for complications associated with higher
glycation rates. This study was limited by a single FPG mea-
surement to determine the relationship with HbA1c, so we could
not take diurnal changes in plasma glucose into account. A
measure of average glucose would have been preferred, but
was not available in our data and might not be in clinical prac-
tice where individuals often use oral glucose-lowering medica-
tion only. The DCCT used seven-point glucose profiles to as-
sess HGI [21], while ACCORD used FPG only [16].
In conclusion, we found that HGI predicted macro- and
microvascular complications and mortality, but was no better
than HbA1c, which was a stronger predictor for these out-
comes. Moreover, HbA1c is simpler than HGI. High HGI does
predict risk for mortality with intensive treatment, but results
are the opposite of those from ACCORD. Bringing all this
together, the evidence does not support the clinical relevance
and usefulness of HGI above HbA1c.
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events 11,083 1142 10.3
1.14 (1.07, 1.20) <.0001
1.19 (1.13, 1.26) <.0001
Major microvascular
events 11,083 1129 10.2
1.17 (1.11, 1.23) <.0001
1.31 (1.24, 1.38) <.0001
Total mortality 11,083 1025 9.2
1.16 (1.09, 1.23) <.0001
1.21 (1.14, 1.28) <.0001
Severe
hypoglycaemia 11,083 230 2.1
0.8 1.0 1.2 1.4 1.6
1.10 (0.97, 1.25) 0.123
1.10 (0.97, 1.26) 0.131
HR
Fig. 2 Multivariable Cox proportional hazard regression analysis for
major macrovascular events, major microvascular events, total mortality
and severe hypoglycaemia predicted by continuous HGI and HbA1c per
SD increase (1 SD of HGI is 1.20. 1 SD of HbA1c is 1.56%). Major
macrovascular events were defined as death from a cardiovascular cause,
non-fatal myocardial infarction or stroke. Major microvascular events
were defined as new or worsening nephro- or retinopathy. Severe
hypoglycaemic episodes were defined as transient dysfunction of the
central nervous system with the inability to treat oneself. Model was
adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration
of type 2 diabetes, history of macro- and microvascular events, current
drinking and smoking, use of glucose-lowering drugs, use of BP-lower-
ing drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR),
LDL-, HDL- and total cholesterol, triacylglycerol. Diamonds, HGI; cir-
cles, HbA1c
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